FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
Top News Most Read Highlighted
Get Alerts ALR Hot Sheet
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend: Up
Today’s Overall Ratings:
Up: 22 | Down: 24 | New: 15
Alere, Inc. (NYSE: ALR) could be one to gain as the flu season in the U.S. picks up.
Jefferies recently commented on the prospects for Alere this year as the season ramps up. The firm correlated ALere’s “North American flu sales and the various statistics captured in the CDC’s FluView report in attempt to estimate the incremental benefit in the company’s 4Q:12 and 1Q:13 results,” and sees a $7 million to $16 million incremental benefit over the next two quarters.
Early in January, Alere’s counterpart, Quidel (Nasdaq: QDEL), released strong preliminary fourth-quarter results, due to a “sudden and early onset to this year’s influenza season.”
Jefferies has a Buy rating on Alere and price target of $26. Shares are just about flat on the session today.
For more on influenza vaccine providers that might see a little movement, click here.
For an analyst ratings summary and ratings history on Alere click here. For more ratings news on Alere click here.
Shares of Alere closed at $20.86 yesterday, with a 52 week range of $17.13-$27.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW